ABNORMAL GROWTH-HORMONE DYNAMICS IN CHRONIC LIVER-DISEASE DO NOT DEPEND ON SEVERE PARENCHYMAL DISEASE

被引:24
作者
ASSAAD, SN
CUNNINGHAM, GR
SAMAAN, NA
机构
[1] UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST,CTR CANC,DIV MED, ENDOCRINOL SECT,1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA
[2] VET ADM MED CTR, DEPT MED, HOUSTON, TX 77211 USA
[3] BAYLOR UNIV, HOUSTON, TX 77030 USA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1990年 / 39卷 / 04期
关键词
D O I
10.1016/0026-0495(90)90248-B
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Abnormal basal serum levels of growth hormone (GH) and abnormal GH dynamics have been observed in patients with alcoholic cirrhosis (AC). To further characterize these abnormalities, patients with AC or schistosomal hepatic fibrosis (SHF) were evaluated. The former patients have parenchymal liver disease, portal hypertension, and portosystemic shunting. SHF, in contrast, is characterized by periportal fibrosis with minimal or no parenchymal cell disease, portal hypertension, and portosystemic shunting. We studied 20 patients with SHF and normal stature and 15 patients with AC. In these two groups of patients, basal serum GH was higher than normal (P < .01). A paradoxical increase in GH was observed during the oral glucose tolerance test (OGTT) in 55% of SHF and in 40% of AC patients. Significant GH elevation followed thyrotropin-releasing hormone (TRH) administration in 80% of SHF and 66% of AC patients, but not in normals. Serum nonsuppressible insulin-like activity (NSILA) and serum somatomedin C (Sm-C) levels were reduced significantly in both groups. In SHF patients, the paradoxical increase in GH during OGTT correlated inversely with Sm-C (r = -.6, P < .05). We conclude that (1) abnormal GH secretion occurs in both SHF and AC, (2) serum Sm-C and NSILA are diminished in both forms of liver disease, and (3) portosystemic shunting of blood appears to be the important pathology shared by both forms of liver disease. © 1990.
引用
收藏
页码:349 / 356
页数:8
相关论文
共 54 条
[51]   ACUTE AND CHRONIC ESTROGEN EFFECTS UPON SERUM SOMATOMEDIN ACTIVITY, GROWTH-HORMONE, AND PROLACTIN IN MAN [J].
WIEDEMANN, E ;
SCHWARTZ, E ;
FRANTZ, AG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1976, 42 (05) :942-952
[52]   REDUCED SERUM SOMATOMEDIN ACTIVITY IN PATIENTS WITH CHRONIC LIVER-DISEASE [J].
WU, A ;
GRANT, DB ;
HAMBLEY, J ;
LEVI, AJ .
CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1974, 47 (04) :359-366
[53]  
ZANOBONI A, 1977, J CLIN ENDOCR METAB, V45, P576, DOI 10.1210/jcem-45-3-576
[54]   NONSUPPRESSIBLE INSULIN-LIKE ACTIVITY (NSILA) FROM HUMAN-SERUM - RECENT ACCOMPLISHMENTS AND THEIR PHYSIOLOGIC IMPLICATIONS [J].
ZAPF, J ;
HUMBEL, RE ;
FROESCH, ER .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1978, 27 (12) :1803-1828